Mechanism:HER2xCD3 (bispecific mAb)
Primary Indication:HER2 positive cancers such as breast Cancer, gastric cancer & ovarian Cancer
GBR 1302, a HER2xCD3 bispecific antibody, is the first clinical candidate based on Glenmark’s proprietary best in class BEAT® platform and also GBR 1302 is Glenmark’s first clinical candidate targeting oncology indications. The BEAT® antibody technology platform facilitates the efficient development and manufacturing of antibodies with dual specificities called bispecific antibodies. .
GBR 1302, a HER2xCD3 bi-specific antibody has successfully completed the preclinical evaluation phase. In pre-clinics, GBR 1302 has demonstrated superiority over current antibody therapies against most HER2 positive cancers, including breast cancer. Glenmark has submitted an application to conduct Phase 1 clinical trials for GBR 1302 with the Paul Ehrlich Institute (PEI), Germany, and expects to initiate dosing in this financial year. If confirmed in clinical trials, GBR 1302 could constitute an innovative treatment for HER2 positive cancers, potentially superior to the currently available monoclonal antibody treatments.